Urticaria

P Kolkhir, AM Giménez-Arnau, K Kulthanan… - Nature Reviews …, 2022 - nature.com
Urticaria is an inflammatory skin disorder that affects up to 20% of the world population at
some point during their life. It presents with wheals, angioedema or both due to activation …

Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases

P Kolkhir, D Elieh-Ali-Komi, M Metz… - Nature Reviews …, 2022 - nature.com
Mast cells have crucial roles in allergic and other inflammatory diseases. Preclinical
approaches provide circumstantial evidence for mast cell involvement in many diseases, but …

Anti‐IL‐5 therapies for asthma

HA Farne, A Wilson, S Milan, E Banchoff… - Cochrane Database …, 2022 - cochranelibrary.com
Antecedentes Esta la segunda actualización de una revisión publicada anteriormente en la
Biblioteca Cochrane (2015, primera actualización en 2017). La interleucina 5 (IL‐5) es la …

Type 2 chronic inflammatory diseases: targets, therapies and unmet needs

P Kolkhir, CA Akdis, M Akdis, C Bachert… - Nature Reviews Drug …, 2023 - nature.com
Over the past two decades, significant progress in understanding of the pathogenesis of type
2 chronic inflammatory diseases has enabled the identification of compounds for more than …

The pathogenesis of chronic spontaneous urticaria: the role of infiltrating cells

AM Giménez-Arnau, L de Montjoye, R Asero… - The Journal of Allergy …, 2021 - Elsevier
Chronic spontaneous urticaria is characterized by a perivascular non-necrotizing cellular
infiltrate around small venules of the skin. It consists primarily of CD4 (+) lymphocytes, a …

Eosinophil knockout humans: uncovering the role of eosinophils through eosinophil-directed biological therapies

EA Jacobsen, DJ Jackson, E Heffler… - Annual review of …, 2021 - annualreviews.org
The enigmatic eosinophil has emerged as an exciting component of the immune system,
involved in a plethora of homeostatic and inflammatory responses. Substantial progress has …

[HTML][HTML] An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria

S Altrichter, P Staubach, M Pasha, B Singh… - Journal of Allergy and …, 2022 - Elsevier
Background Chronic urticaria (CU) is a debilitating mast cell–driven disease, often refractory
to standard therapy (ie, antihistamines). Lirentelimab, an anti–sialic acid–binding …

Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial

KL Kliewer, C Murray-Petzold, MH Collins… - The Lancet …, 2023 - thelancet.com
Background In eosinophilic gastrointestinal diseases, the role of eosinophils in disease
pathogenesis and the effect of eosinophil depletion on patient outcomes are unclear …

Chronic urticaria: advances in understanding of the disease and clinical management

L He, W Yi, X Huang, H Long, Q Lu - Clinical reviews in allergy & …, 2021 - Springer
Chronic urticaria (CU) is a common skin condition characterized by the recurrence of
wheals, with or without angioedema, which lasts for at least 6 weeks. Owing to its pruritus …

Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment

T Zuberbier, LF Ensina, A Giménez-Arnau, C Grattan… - The Lancet, 2024 - thelancet.com
Chronic urticaria is a common and debilitating mast cell-driven skin disease presenting with
itchy wheals, angio-oedema, or both. Chronic urticaria is classified as spontaneous (without …